Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America

Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America.

PROLONG PHARMACEUTICALS JOINS NEW SICKLE CELL DISEASE COALITION, ISSUES CALL TO ACTION TO IMPROVE TREATMENT AND CARE

Prolong Pharmaceuticals joins other leading patient advocacy groups, researchers, clinicians, policymakers, industry, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research, both in the United States and globally...

Prolong Pharmaceuticals Presents Data on Unique “Un-Sickling” In Vitro Activity Observed in Sickle Cell Investigational Drug SANGUINATE™

SOUTH PLAINFIELD, NJ, April 14, 2015 /PRNewswire/ -- Prolong announced today that it had presented data on its flagship product SANGUINATE, reporting its novel ability to rapidly reverse sickling of human red blood cells...

Prolong Pharmaceuticals’ Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA

SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- Prolong announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its flagship product SANGUINATE...

Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team

SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced...

Prolong Pharmaceuticals Presents Phase 1 Results For Flagship Product SANGUINATE™

SOUTH PLAINFIELD, N.J., Oct. 3, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company developing products to treat several diseases and their debilitating comorbidities presented Phase I results of its lead product, SANGUINATE™ at the...